Gale

Gale Therapeutics was a clinical-stage biopharmaceutical company focused on the development and commercialization of cancer immunotherapy product candidates. The company's lead program was NeuVax (norgestimate), a peptide-based immunotherapy designed to prevent breast cancer recurrence in patients with low-to-moderate HER2 expression. Gale's pipeline also included GALE-301, a vaccine targeting folate receptor alpha, and GALE-401, a controlled-release version of anagrelide for myeloproliferative neoplasms. In December 2017, the company completed a business combination with Sellas Life Sciences Group, which now manages the legacy oncology assets. The merger followed significant clinical and regulatory challenges, including the early termination of a Phase 3 trial for NeuVax.